Financial details are yet to be disclosed by either company.
The acquisition will provide Texas-based Integer with research and development, as well as a sales centre in Israel, expected to strengthen the company’s portfolio with the addition of catheter design, clinical, and pilot manufacturing capabilities.
Integer president and CEO Joe Dziedzic said: “Acquiring Inomec strengthens our research and development pipeline by adding differentiated capabilities and expanding our global footprint in a key market with an extensive innovation ecosystem that is widely recognized as a leader in MedTech innovation.”
Inomec, set up in 2008, is involved in research, development and manufacturing of medical devices including metal implants, minimally invasive tools, delivery systems, laser processing services and drug-device combination devices.
Bio-compatible 3D printing, clinical and pilot manufacturing, polymer and metallic laser welding, and cleanroom assembly and packaging services are among the capabilities of Inomec.
Inomec in Israel is expected to become a significant research and development centre, alongside Plymouth and Chaska in Minnesota, Clarence in New York, Beaverton Oregon, Raynham, Massachusetts, Montevideo, Uruguay, and Galway, Ireland.
The centre will allow Integer inclusion in a pipeline of early and late-stage startups, as well as multinational medical device technology firms in Israel.
It will offer added research and development capabilities to Integer’s other manufacturing facilities across the world.
It focuses on markets such as cardiac, vascular, portable medical, neuromodulation, advanced surgical and orthopaedics, also producing batteries for high-end niche applications in energy, military, and environmental markets.